Research
Molecular
Regulatory strategies adopted by the FDA include risk evaluation and mitigation strategies and post-marketing safety trials.
Practitioners should be aware of these regulatory measures when considering the safety of weight loss medications.
StrongSupportsmedium confidence
Regulatory strategies adopted by the FDA to manage the potential for uncommon but potentially serious post-marketing toxicity include: (i) risk evaluation and mitigation strategy programmes; (ii) stipulating post-marketing safety trials.
Why this rating
The claim is based on a detailed description of regulatory practices.
Source
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Andrew J. Krentz et al. · Diabetes Obesity and Metabolism · 2016
DOI 10.1111/dom.12657
reviewCited 167×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →